None listed
Conditions
Brief summary
Type 1 diabetes (T1D) results from the killing of insulin-producing pancreatic beta cells by cells of the immune system. We aim to slow the progressive, immune-mediated loss of insulin-producing beta cells that occurs after clinical presentation. We have identified a pathway that is important for immune cells to kill beta cells, and a drug that will block this pathway and prevent beta cell death. This drug, baricitinib, is already in clinical use for rheumatoid arthritis, and is currently in clinical trials for other diseases, including childhood autoimmune diseases. We hypothesize that baricitinib treatment for 48 weeks will preserve beta cell function in children and young adults with recently-diagnosed T1D. The trial aims to recruit 83 participants aged 12-30 years who have been recently diagnosed with T1D. Two thirds of the participants will be randomly assigned to receive baricitinib, one third will receive placebo. Our trial will test if baricitinib can slow the progressive loss of insulin-producing beta cells in these patients. The primary objective is to determine if baricitinib can reduce the loss of meal-stimulated plasma C-peptide, a measure of beta-cell function. Maintaining endogenous insulin in recent-onset T1D improves glucose control and may lead to long-term improvements in glucose and lower rates of serious diabetes complications and death.
Interventions
Baricitinib is an oral JAK1/JAK2-selective inhibitor.
Dosage: The dose of baricitinib is 1 x 4mg tablet once daily
Duration of administration: 48 weeks
Mode of administration: Orally, with or without food
Assessment of intervention adherence: Tablet counts will be used to assess participant compliance with daily doses of the study medication
Sponsors
St Vincent’s Institute of Medical Research
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
10 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
To be eligible for study entry, participants must satisfy all of the following criteria: 1. Male or female aged between 10 and 30 years (inclusive) at screening; 2. Diagnosis of T1D according to ADA criteria within 100 days prior to starting study drug; 3. Islet autoantibody positivity (one or more of: GADA, IA-2A, IAA (assessed within one week of commencing insulin therapy), ZnT8A); 4. Stimulated (peak or 90 min) C-peptide >0.2 nM during a 2-hour MMTT at the screening visit, or random C-peptide result >0.3 nM during the screening period; 5. Participants of childbearing age who are sexually active must agree to use of effective birth control until the end of the study; 6. Be able to read, understand and give written informed consent; 7. Be willing to comply with intensive diabetes management.
Exclusion criteria
Participants will be excluded from the study if one or more of the following criteria are applicable: 1. Use of immunosuppressive or immunomodulatory therapies other than inhaled or topical glucocorticoids; 2. Current or past history of deep vein thrombosis or pulmonary embolism; 3. Impaired renal function defined by estimated glomerular filtration rate (according to the CKD-EPI) of < 60 mL/min/1.73 m2; 4. LDL cholesterol >4mmol/l; 5. Elevated liver function tests at screening: a. Aspartate aminotransferase 2x ULN b. Alanine aminotransferase 2 x ULN; 6. Clinically significant abnormal laboratory parameters at screening including but not limited to: a. Hemoglobin < 8 g/L; b. White blood cells <2500 cells/µl; c. Lymphocyte count <750 cells/µl; d. Platelets <50,000 cells/µl; e. Neutrophils <1200cells/µL; 7. Known hypersensitivity to baricitinib; 8. Known malignancy with the exception of successfully treated non- metastatic basal cell and squamous cell carcinoma; 9. Pregnancy, a desire for pregnancy, breast feeding, or a desire to father a child during the study; 10. Patients with current or recent (within 12 weeks of screening) clinically significant comorbidity, including clinically serious viral, bacterial, fungal, or parasitic infection. Viral infections include HBV, HCV, EBV, HIV, recent herpes zoster and TB; 11. Treatment with any investigational product within 30 days or 5 half - lives (whichever is longer) prior to baseline visit, or concurrent participation in a clinical trial with an investigational product or device; 12. Experienced any of the following within 12 weeks of screening: myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association Stage IV heart failure; 13. Any serious medical condition within the previous 4 weeks which places the participant at an unacceptable risk if he or she were to participate in the study or confounds the ability to interpret data from the study, including, but not limited to, symptomatic cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine, haematological and neurological conditions or psychiatric illness/social situations that would limit compliance with study requirements; 14. Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study that, in the opinion of the investigator would pose an unacceptable risk to the participant; 15. History of chronic alcohol abuse or IV drug abuse or other illicit drug abuse within 2 years prior to screening.
Outcome results
None listed